Skip to main content
Premium Trial:

Request an Annual Quote

FDA Puts Tekmira Ebola Drug Study on Hold

Premium

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals said this week that it has been notified that the US Food and Drug Administration has placed a hold on a Phase I study of the company's siRNA-based Ebola virus drug, TKM-Ebola.

According to Tekmira, the single ascending dose portion of the study, in which TKM-Ebola was administered to healthy volunteers without the use of steroid premedication to prevent immunostimulatory side effects.

"The FDA has requested additional data related to the mechanism of cytokine release, observed at higher doses, which we believe is well understood, and a protocol modification designed to ensure the safety of healthy volunteer subjects, before we proceed with the multiple ascending dose portion" of the study, Tekmira President and CEO Mark Murray said in a statement.

"We will continue our dialogue with the FDA, provided for under our fast track status, in order to advance the development of this important therapeutic agent," he added.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.